[EBS] Emergent Biosolutions, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 33.6 Change: 0.1 (0.3%)
Ext. hours: Change: 0 (0%)

chart EBS

Refresh chart

Strongest Trends Summary For EBS

EBS is in the long-term up 53% above S&P in 11 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Emergent BioSolutions Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. The Biodefense segment markets BioThrax, an FDA approved vaccine for the prevention of anthrax disease; BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine) for the treatment of suspected or documented exposure to botulinum neurotoxin A, B, C, D, E, F, or G; Vaccinia Immune Globulin Intravenous for counteracting complications associated with the smallpox vaccine; and RSDL (decontamination lotion) to remove and/or neutralize chemical warfare agents from the skin. This segment is also developing Anthrax Immune Globulin Intravenous to treat toxemia associated with inhalational anthrax; NuThrax, an anthrax vaccine in Phase II clinical trials, which is based on BioThrax combined with CPG 7909, an adjuvant licensed from Pfizer Inc.; an

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -42.32% Sales Growth - Q/Q-57% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA3.86% ROE6.59% ROI4.26%
Current Ratio5.05 Quick Ratio4.03 Long Term Debt/Equity0.77 Debt Ratio0.15
Gross Margin74.31% Operating Margin12% Net Profit Margin7.71% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities11 M Cash From Investing Activities-9.08 M Cash From Operating Activities-65.87 M Gross Profit44.88 M
Net Profit-21.52 M Operating Profit-28.31 M Total Assets917.85 M Total Current Assets405.81 M
Total Current Liabilities80.3 M Total Debt251 M Total Liabilities379.97 M Total Revenue63.63 M
Technical Data
High 52 week73.24 Low 52 week39.92 Last close43.62 Last change-0.93%
RSI53.62 Average true range1.93 Beta0.83 Volume333.02 K
Simple moving average 20 days-0.45% Simple moving average 50 days-2.41% Simple moving average 200 days-20.53%
Performance Data
Performance Week-2.68% Performance Month-0.11% Performance Quart-6.58% Performance Half-25.55%
Performance Year-18.66% Performance Year-to-date-25.68% Volatility daily2.28% Volatility weekly5.11%
Volatility monthly10.46% Volatility yearly36.25% Relative Volume180.22% Average Volume378.21 K
New High New Low


2020-06-05 19:39:21 | Emergent BioSolutions Statement on U.S. District Court Decision

2020-06-03 13:42:00 | Emergent BioSolutions Picks Up a _Warp Speed_ Contract to Manufacture Coronavirus Vaccines

2020-06-01 09:34:25 | U.S. awards new $628 million contract to boost output of potential COVID-19 vaccine

2020-06-01 07:50:18 | U.S. awards new $628 mln contract to boost output of potential COVID-19 vaccine

2020-06-01 06:30:10 | Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing

2020-05-30 11:31:03 | Emergent Biosolutions EBS Up 12.9% Since Last Earnings Report: Can It Continue?

2020-05-26 12:05:00 | How to Play Emergent Biosolutions' Continuing Rally

2020-05-21 11:19:13 | A Rising Share Price Has Us Looking Closely At Emergent BioSolutions Inc.'s NYSE:EBS P/E Ratio

2020-05-18 17:28:32 | Stocks Amid COVID-19 Outbreak: Winners So Far in the Health Industry

2020-05-17 09:31:00 | Is Buying a Basket Loaded With Every Coronavirus Vaccine Stock a Smart Strategy?

2020-05-16 09:04:00 | Is Emergent BioSolutions Stock a Buy?

2020-05-16 07:33:00 | Better Coronavirus Stock: Johnson & Johnson or Emergent BioSolutions?

2020-05-14 11:51:09 | Coronavirus Vaccine Progress Accelerates

2020-05-12 06:00:10 | Emergent BioSolutions to Participate in Virtual Investor Conferences

2020-05-07 11:14:49 | How Does Emergent BioSolutions's NYSE:EBS P/E Compare To Its Industry, After Its Big Share Price Gain?

2020-05-07 09:20:10 | Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 21, 2020 at 9:00am EDT

2020-05-05 08:10:00 | Vaccine Maker Emergent BioSolutions Could Surge Higher in the Months Ahead

2020-05-04 13:21:05 | Emergent EBS Earnings and Revenues Beat Estimates in Q1

2020-05-01 06:45:19 | Edited Transcript of EBS earnings conference call or presentation 30-Apr-20 9:00pm GMT

2020-05-01 04:01:01 | Emergent BioSolutions Inc EBS Q1 2020 Earnings Call Transcript

2020-04-30 18:35:10 | Emergent Biosolutions EBS Surpasses Q1 Earnings and Revenue Estimates

2020-04-30 16:08:53 | Emergent BioSolutions Reports Financial Results for First Quarter 2020

2020-04-29 12:47:04 | Vaxart VXRT to Report Q1 Earnings: What's in the Cards?

2020-04-29 08:48:00 | Is Emergent BioSolutions the Next Hot Coronavirus Stock?

2020-04-24 16:21:16 | Covid Report: How A J&J Vaccine Deal Sent This Biotech Stock Flying

2020-04-24 09:57:00 | Emergent BioSolutions, Johnson & Johnson Sign Virus-Vaccine Accord

2020-04-24 08:37:04 | D.C.-area leaders cautiously turn their eyes toward reopening the economy

2020-04-24 08:32:00 | J&J to pay Emergent $135 million as part of COVID-19 vaccine manufacturing deal

2020-04-23 23:00:33 | J&J strikes deal with Emergent BioSolutions on coronavirus vaccine manufacturing

2020-04-23 18:51:43 | Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19

2020-04-23 12:32:04 | Will Emergent Biosolutions EBS Report Negative Earnings Next Week? What You Should Know

2020-04-22 11:19:03 | Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates

2020-04-21 16:55:10 | Emergent BioSolutions Appoints Dr. Karen L. Smith as Chief Medical Officer

2020-04-19 08:34:41 | How Does Emergent BioSolutions's NYSE:EBS P/E Compare To Its Industry, After Its Big Share Price Gain?

2020-04-17 14:25:00 | Emergent BioSolutions Is Safe Way to Bet on Covid-19 Vaccines: Portfolio Manager

2020-04-17 06:00:00 | Emergent- Adding Value to Vaccines

2020-04-16 06:30:10 | Emergent BioSolutions to Release First Quarter 2020 Financial Results and Conduct Conference Call on April 30, 2020

2020-04-14 03:08:00 | We Are Dropping Coverage of Erste Group Bank

2020-04-08 06:00:00 | Novavax to start coronavirus vaccine trials sooner than planned

2020-04-06 06:30:10 | Emergent BioSolutions Appoints Nina DeLorenzo as Senior Vice President of Global Public Affairs

2020-04-05 13:07:00 | Emergent BioSolutions, Eyeing Two Plasma Therapies for Covid-19, Wins Fed's Help

2020-04-03 14:26:03 | These D.C.-area biotech companies are making progress on COVID-19. Here’s the latest.

2020-04-03 12:54:36 | Emergent BioSolutions gets $14.5M in federal funding to expedite COVID-19 plasma therapy development

2020-04-03 07:36:23 | The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO

2020-04-02 16:05:10 | Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19

2020-04-02 14:51:56 | Exclusive: Rockville bio raising $50M, building COVID-19 vaccine — and plotting IPO

2020-04-01 09:42:45 | Tiny Bay Area company aims to win coronavirus vaccine race with a tablet

2020-03-31 17:35:15 | Novavax names manufacturing partner for flu vaccine

2020-03-31 16:05:10 | Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™

2020-03-31 14:13:00 | These 19 companies are working on coronavirus treatments or vaccines — here’s where things stand